Open access
Open access
Powered by Google Translator Translator

Phase 2 RCT | Deintensified chemoradiotherapy for pretreatment Epstein-Barr Virus DNA-selected low-risk locoregionally advanced nasopharyngeal carcinoma.

19 Jul, 2022 | 12:58h | UTC

Deintensified Chemoradiotherapy for Pretreatment Epstein-Barr Virus DNA-Selected Low-Risk Locoregionally Advanced Nasopharyngeal Carcinoma: A Phase II Randomized Noninferiority Trial – Journal of Clinical Oncology (link to abstract – $ for full-text)

Commentaries:

#VisualAbstract: Pretreatment with radiotherapy and two cycles of concurrent cisplatin may reduce toxicity in locally advanced nasopharyngeal carcinoma – Physician’s Weekly

Intensity-Modulated Radiotherapy Plus 2 Cycles of Concurrent Cisplatin Improved Low-Risk LA-NPC Outcomes – Cancer Network

 

Commentary on Twitter

 


Stay Updated in Your Specialty

No spam, just news.